Clin2
NCT04621435Possibly a fitRecruiting

PET imaging test for solid tumors using FAP-2286

Solid Tumors, AdultMetastatic Cancer

Part of Cancer clinical trials.

This Phase 1 study tests a special imaging scan (using FAP-2286) to see solid tumors in people who have already been diagnosed. It may help doctors better detect where cancer is in the body and how to plan treatment.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
191 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • Be 18 years old or older
  • Have a confirmed solid tumor diagnosis (not just suspected cancer)
  • Have cancer in one of these groups: metastatic disease, no known spread, or high-risk early disease where spread would change treatment plans
  • Be willing and able to sign informed consent and follow study steps
  • Not be pregnant

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07144085Recruiting· Phase 1
Testing a new PET scan tracer for cancer diagnosis

This trial tests a new type of PET/CT scan that uses a special tracer (called ⁶⁸Ga-FXX489) to help find and diagnose cancers. It is for people who are strongly suspected to have cancer and want to see if this new imaging method can help their doctors learn more about their disease.

Shenyang, Liaoning
NCT07707999Not yet recruiting· Early Phase 1
Imaging test for solid tumors using FAP-targeted radionuclide

This study uses a special imaging agent that targets a protein called FAP found on many solid tumors. It helps doctors see tumors more clearly and stage them better. If you have a confirmed solid tumor and are able to undergo PET or SPECT/CT scans, this trial may help improve how your cancer is evaluated.

Wuhan, Hubei
NCT07708103Not yet recruiting· Early Phase 1
Testing a new PET scan agent for solid tumors

This study tests a new PET/CT imaging agent (gallium-68 FFD) to see how well it works in both healthy volunteers and people with solid tumors. It could help doctors find or monitor cancer more accurately.

Wuhan, Hubei
NCT06790264Recruiting
Special PET Scan for Breast Cancer - FAPi Imaging

This trial uses a special PET scan (68Ga-FAPi-46) to see how breast cancer interacts with nearby cells. It may help doctors understand your tumor better and guide treatment decisions, especially if you are planning surgery or chemotherapy before surgery.

Milan, Italy
NCT07741006Enrolling by invitation· Early Phase 1
PET imaging study for adults with solid tumors

This study tests a new PET imaging agent called [68Ga]Ga-ELI411 to help see tumors more clearly. It is for adults with solid tumors who are already scheduled for a standard PET scan, and may help doctors better understand and manage their cancer.

Wuhan, Hubei
NCT06684028Recruiting
PET imaging of a new tracer for cancer patients

This study uses a new imaging agent called [68Ga]-FAPI-JNU to take detailed pictures of tumors with a PET/CT scan. It aims to see how well this tracer works in people with various types of cancer.

Wuxi, Jiangsu

Hear when a new Metastatic Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.